These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
955 related articles for article (PubMed ID: 18456496)
1. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496 [TBL] [Abstract][Full Text] [Related]
2. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526 [TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
4. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985 [TBL] [Abstract][Full Text] [Related]
5. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114 [TBL] [Abstract][Full Text] [Related]
6. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257 [TBL] [Abstract][Full Text] [Related]
7. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920 [TBL] [Abstract][Full Text] [Related]
9. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995 [TBL] [Abstract][Full Text] [Related]
10. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759 [TBL] [Abstract][Full Text] [Related]
11. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174 [TBL] [Abstract][Full Text] [Related]
12. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958 [TBL] [Abstract][Full Text] [Related]
13. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948 [TBL] [Abstract][Full Text] [Related]
14. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Mueller RE; Parkes RK; Andrulis I; O'Malley FP Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438 [TBL] [Abstract][Full Text] [Related]
16. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533 [TBL] [Abstract][Full Text] [Related]
17. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Gennari A; Pronzato P Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039 [TBL] [Abstract][Full Text] [Related]
18. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419 [TBL] [Abstract][Full Text] [Related]
19. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769 [TBL] [Abstract][Full Text] [Related]
20. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy. Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]